Corinfar sustained release pills 10mg, 50pcs

Composition

1 coated tablet contains:

nifedipine 10 mg

Pharmacological action

Corinfar is a class II selective calcium channel blocker, a dihydropyridine derivative.

Causes antianginal and hypotensive effects. Relaxes the smooth muscles of blood vessels. Relieves spasm and dilates the coronary and peripheral arteries.

Reduces peripheral resistance and slightly-myocardial contractility, reduces afterload on the heart and myocardial oxygen demand. Improves coronary blood flow and post-stenotic circulation in patients with atherosclerotic obstruction.

It does not inhibit automatism and myocardial conduction.

When using Corinfar, reflex tachycardia may occur.

Indications

-Stable angina pectoris. – Arterial hypertension. – Angiospastic angina (Prinzmetal angina, variant angina pectoris).

Use during pregnancy and lactation

Corinfar is contraindicated for use during pregnancy.

If it is necessary to use Corinfar during lactation, the question of stopping breastfeeding should be decided.

Contraindications

: arterial hypotension (systolic blood pressure below 90 mm Hg);- cardiogenic shock, collapse— – chronic heart failure in the stage of decompensation;- severe aortic stenosis;- unstable angina; – acute myocardial infarction (first 4 weeks);- co-use with rifampicin;- pregnancy (I trimester);- lactation period;- hypersensitivity to nifedipine and other 1,4-dihydropyridine derivatives or to other components of Corinfar. Caution: mitral valve stenosis, hypertrophic obstructive cardiomyopathy, bradycardia or tachycardia, sick sinus syndrome node, malignant hypertension, hypovolemia, severe cerebrovascular disorders, myocardial infarction with left ventricular failure, obstruction of the gastrointestinal tract, renal and hepatic insufficiency, hemodialysis (due to the risk of arterial hypotension), pregnancy (II and III trimester), age 18 years (effectiveness and safety not established), concomitant use of beta-blockers, digoxin

Side effects

From the cardiovascular system: tachycardia, palpitations, arrhythmias, peripheral edema (ankles, feet, shins), manifestations of excessive vasodilation (asymptomatic decrease in blood pressure, development or aggravation of heart failure, “hot flashes” of blood to the skin of the face, hyperemia of the skin of the egg, a feeling of heat), a pronounced decrease in blood pressure (rarely), syncope. In some patients, especially at the beginning of treatment or with an increase in the dose, angina attacks may occur and in some cases-the development of myocardial infarction, which requires discontinuation of the drug.

From the central nervous system: headache, dizziness, general weakness, fatigue, drowsiness. Long-term use of the drug in high doses – paresthesia of the extremities, tremor, extrapyramidal (Parkinsonian) disorders (ataxia, “masklike” face, shuffling gait, tremor of the hands and fingers, difficulty swallowing), depression.

From the digestive system: dyspepsia (nausea, diarrhea or constipation), dry mouth, flatulence, increased appetite. Rarely-gum hyperplasia, which completely disappears after discontinuation of the drug. With prolonged use-impaired liver function (intrahepatic cholestasis, increased activity of hepatic transaminases).

From the musculoskeletal system: arthritis, myalgia, swelling of the joints, cramps of the upper and lower extremities.

Allergic reactions: rarely-pruritus, urticaria, exanthema, autoimmune hepatitis, exfoliative dermatitis, photodermatitis, anaphylactic reactions

Hematopoietic disorders: anemia, leukopenia, thrombocytopenia, thrombocytopenic purpura, agranulocytosis.

From the urinary system: increased daily diuresis, deterioration of renal function (in patients with renal insufficiency).

Other: rarely-visual disturbances (including transient blindness at the maximum concentration of nifedipine in blood plasma), gynecomastia (in elderly patients, polyp disappears after discontinuation), galactorrhea, hyperglycemia, pulmonary edema, bronchospasm, weight gain.

Interaction

With the simultaneous use of Corinfar with beta-blockers, diuretics, and other antihypertensive drugs, an increase in the hypotensive effect of Corinfar is noted.

With the simultaneous use of Corinfar with nitrates, an increase in the antianginal effect of Corinfar is noted.

With the simultaneous use of Corinfar and tricyclic antidepressants, cimetidine, ranitidine, it is possible to increase the effects of Corinfar.

When Corinfar was co-administered with quinidine, a decrease in the concentration of quinidine in blood plasma was observed in some cases.

When Corinfar was co-administered with digoxin and theophylline, a decrease in the concentration of the latter in blood plasma was observed in some cases.

How to take, course of use and dosage

Set individually depending on the severity of the disease.

In the treatment of stable and angiospastic angina pectoris and arterial hypertension, the drug is prescribed 10 mg (1 tab. ) 2-3 times a day. If the clinical effect is not sufficiently pronounced, it is possible to gradually increase the dose to 20-40 mg (2-4 tablets) 2 times a day.

The maximum daily dose is 80 mg.

Interval between two single doses of 20 mg (2 tablets) must not be less than 4 hours. If the drug is prescribed twice a day, the tablets should be taken approximately 12 hours later (in the morning and in the evening).

The drug should be taken after a meal, without chewing and with a sufficient amount of liquid.

Overdose

Symptoms: in severe cases-loss of consciousness up to the development of coma, hypotension, tachy / bradycardia, hyperglycemia, metabolic acidosis, hypoxia, cardiogenic shock with pulmonary edema.

Treatment: copious gastric lavage, if necessary, in combination with small bowel lavage. When using laxatives, it is necessary to take into account the decrease in intestinal muscle tone up to intestinal atony observed with the use of calcium channel blockers. Since nifedipine is not excreted during hemodialysis, it is not advisable to conduct it. Plasmapheresis is recommended.

With the development of bradycardia, atropine and/or beta-sympathomimetics should be prescribed; with life-threatening bradycardia, a heart rate driver should be implanted for a while.

In case of hypotension, which is a consequence of cardiogenic shock and dilation of arterial vessels,1-2 g of calcium gluconate is administered intravenously, intravenous drip – dopamine (up to 25 mcg/kg body weight/min), dobutamine-up to 15 mcg / kg body weight/min), epinephrine (epinephrine) or norepinephrine (norepinephrine). The content of calcium in the blood serum is maintained at a normal or slightly elevated level.

The introduction of fluid or blood into the body is carried out with caution under the control of hemodynamic parameters.

Special instructions

Caution should be exercised when prescribing Corinfar to patients with severe hypotension (systolic blood pressure less than 90 mm Hg), chronic heart failure in the decompensation phase, as well as patients with severe forms of arterial hypertension and irreversible renal failure and hypovolemia who are on hemodialysis (due to the high risk of a sharp drop in blood pressure).

Discontinue Corinfar gradually, since sudden discontinuation of the drug (especially after prolonged treatment) may lead to withdrawal symptoms.

When drinking alcohol on the background of Corinthar therapy, it is possible to slow down the speed of psychomotor reactions associated with a decrease in blood pressure.

Use in patients with impaired liver function: Corinfar should be prescribed under close supervision to patients with impaired liver function. If necessary, reduce the dose of the drug.

Use in pediatrics: The clinical experience of using the drug in children is insufficient.

Influence on the ability to drive vehicles and manage mechanisms: When taking Corinfar, especially at the beginning of treatment and when changing the drug, it is possible to slow down the speed of psychomotor reactions associated with a decrease in blood pressure. This should be taken into account by persons engaged in potentially dangerous activities that require increased attention and speed of psychomotor reactions.

Form of production

Coated tablets.

Storage conditions

In a dark place, at temperatures below 30 °C

Shelf life

3 years

Active ingredient

Nifedipine

Conditions of release from pharmacies

By prescription

Dosage form

long-acting tablets